Skip to main content
 

Investors & Media

Corporate Profile
At Wave Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, Wave’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi.
Recent News
December 11, 2017
Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND
Lead candidate targets C9ORF72; in vivo animal data demonstrate potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced data from preclinical studies of WVE-3972-01, the company’s investigational stereopure antisense oligonu... 
November 9, 2017
Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2017-- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the third quarter ended September 30, 2017. “Through the growth of talent and capabilities in our organization and excellent execution throughout the quarter, we achieved our ambitious c... 
November 6, 2017
Wave Life Sciences Initiates Clinical Trial for Lead Program in Duchenne Muscular Dystrophy (DMD)
First clinical trial of WVE-210201, an exon 51 skipping investigational therapy, in ambulatory and non-ambulatory boys 5 to 18 years old CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 6, 2017-- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the initiation of a global Phase 1 clinical trial for WVE-210201 in Duchenn... 

view all

Upcoming Events
There are currently no events scheduled.

view all